Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Targanta Therapeutics

1997 FOUNDED
M&A STATUS
21-30 EMPLOYEES
M&A LATEST DEAL TYPE
$42M LATEST DEAL AMOUNT
1 INVESTORS
Description

Developer of innovative antibiotics to treat serious infections in the hospital and other institutional settings. The company develops antibiotics for the treatment of serious gram-positive bacterial infections, including complicated skin and skin structure infections.

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Primary Office
  • 222 Third Street
  • Suite 2300
  • Cambridge, MA 02142
  • United States

+1 (514) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Targanta Therapeutics’s full profile, request a free trial.

Targanta Therapeutics Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Merger/Acquisition 26-Feb-2009 $42M 00000 0000 Completed Clinical Trials - Phase 3
6. IPO 10-Oct-2007 000.00 00000 00000 Completed Clinical Trials - Phase 3
5. Later Stage VC (Series C3) 12-Feb-2007 000.00 00000 00000 Completed Generating Revenue
4. Later Stage VC (Series C2) 06-Jan-2005 0000 0000 000.00 Completed Generating Revenue
3. Later Stage VC (Series C1) 12-Mar-2002 000.00 0000 000.00 Completed Generating Revenue
2. Early Stage VC (Series B) 01-Dec-1999 $28.7M $30.3M 000.00 Completed Product Development
1. Seed Round 01-Dec-1997 $1.58M $1.58M 00.000 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Targanta Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series C3 0,000,000 00.000000 00 000.00 000.00 00 000.00 00.000
Series C2 0,000,000 00.000000 00 000.00 000.00 00 000.00 00.000
Series C1 0,000,000 00.000000 00 000.00 000.00 00 000.00 00.000
Series B 245,000 $0.000100 8% $199.5 $199.5 1x $199.5 1.35%
Series A 20,000 $0.000100 $101.12 $101.12 1x $101.12 0.15%
To view this company’s complete Cap Table, request access »

Targanta Therapeutics Former Investors (13)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Brookside Capital Venture Capital Minority 000 0000 000000 0
Fonds de solidarité FTQ PE/Buyout Minority 000 0000 000000 0
GrowthWorks Venture Capital Minority 000 0000 000000 0
InterMune Corporation 000 0000 000000 0
Le Centre CDP Capital Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 13 investors. Get the full list »

Targanta Therapeutics Executive Team (7)

Name Title Board
Seat
Contact
Info
Mark Leuchtenberger President & Chief Executive Officer
Thomas Parr Ph.D Chief Scientific Officer
Daniel Char Vice President & General Counsel
Roger Miller Vice President, Operations & Manufacturing

3 Former Executives

You’re viewing 4 of 7 executives. Get the full list »

Targanta Therapeutics Board Members (1)

Name Representing Role Since Contact
Info
Randy Berholtz JD Self Board Member 000 0000